Head-to-head · Value Score
Gimme Care vs NowPatient
Two GLP-1 deals, scored on the same six factors. Gimme Care lands a Value Score of 91, NowPatient a 46. Here's who gives you the honest lower price — and where each one bites back.
Gimme Care
#5 · Grade A · Best Value
Est. first month
$130/mo
Save ~90% vs brand-nameNowPatient
#388 · Grade C · Watch List
Est. first month
From $1,069/mo (brand Mounjaro)
The verdict
Gimme Care takes it on Value Score, 91 to 46 — an est. $130/mo first month, with no teaser step-up baked in. NowPatient isn't out of it: Shoppers who want brand-name GLP-1 access without a compounded route.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Gimme Care | NowPatient |
|---|---|---|
| Value Score | 91 (A) | 46 (C) |
| Est. first month | $130/mo | From $1,069/mo (brand Mounjaro) |
| Save vs brand-name | ~90% | — |
| Semaglutide | $130/mo | From $1,349/mo (brand Wegovy) |
| Tirzepatide | $163/mo | From $1,069/mo (brand Mounjaro) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Gimme Care
Genuinely cheap on both molecules ($130 / $163) with a LegitScript-certified pharmacy and all-50-state reach.
Why it's a deal
- Low flat price on both molecules ($130 sema / $163 tirz)
- LegitScript-certified pharmacy
- Available in all 50 states
The fine print
- No brand-name option — compounded only
- No oral/sublingual form
NowPatient
NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.
Why it's a deal
- Free telehealth consultation — you only pay for the medication
- Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
- One of the few platforms offering Wegovy in both injection and oral pill form
- No compounded options — every drug is FDA-approved brand-name
The fine print
- Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
- No compounded semaglutide or tirzepatide (usually the cheaper route)
- State availability determined during intake, not shown upfront
- Does not offer Foundayo (orforglipron)
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Gimme Care is ranked on the Gimme Care alternatives board, and the same list for the other side is on alternatives to NowPatient.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.